JP2021529513A5 - - Google Patents

Info

Publication number
JP2021529513A5
JP2021529513A5 JP2020570046A JP2020570046A JP2021529513A5 JP 2021529513 A5 JP2021529513 A5 JP 2021529513A5 JP 2020570046 A JP2020570046 A JP 2020570046A JP 2020570046 A JP2020570046 A JP 2020570046A JP 2021529513 A5 JP2021529513 A5 JP 2021529513A5
Authority
JP
Japan
Prior art keywords
sequence
vector genome
nucleotide sequence
seq
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529513A (ja
JP7565218B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040230 external-priority patent/WO2020010042A1/en
Publication of JP2021529513A publication Critical patent/JP2021529513A/ja
Publication of JP2021529513A5 publication Critical patent/JP2021529513A5/ja
Application granted granted Critical
Publication of JP7565218B2 publication Critical patent/JP7565218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570046A 2018-07-02 2019-07-02 筋萎縮性側索硬化症および脊髄に関連する障害の治療 Active JP7565218B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693040P 2018-07-02 2018-07-02
US62/693,040 2018-07-02
US201862746104P 2018-10-16 2018-10-16
US62/746,104 2018-10-16
PCT/US2019/040230 WO2020010042A1 (en) 2018-07-02 2019-07-02 Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord

Publications (3)

Publication Number Publication Date
JP2021529513A JP2021529513A (ja) 2021-11-04
JP2021529513A5 true JP2021529513A5 (cg-RX-API-DMAC7.html) 2022-07-11
JP7565218B2 JP7565218B2 (ja) 2024-10-10

Family

ID=67551691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570046A Active JP7565218B2 (ja) 2018-07-02 2019-07-02 筋萎縮性側索硬化症および脊髄に関連する障害の治療

Country Status (7)

Country Link
US (1) US20210254103A1 (cg-RX-API-DMAC7.html)
EP (1) EP3818161A1 (cg-RX-API-DMAC7.html)
JP (1) JP7565218B2 (cg-RX-API-DMAC7.html)
CN (1) CN112567035A (cg-RX-API-DMAC7.html)
AU (1) AU2019299861A1 (cg-RX-API-DMAC7.html)
CA (1) CA3103963A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020010042A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US20220168450A1 (en) * 2019-04-29 2022-06-02 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
EP4291654A2 (en) 2021-02-12 2023-12-20 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
WO2024226761A2 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2025045130A1 (zh) * 2023-08-29 2025-03-06 石药集团中奇制药技术(石家庄)有限公司 一种抑制sod1基因表达的dsrna分子及其应用

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
FR2640638B1 (fr) 1988-12-20 1991-02-15 Commissariat Energie Atomique Bioreacteur et dispositif pour la culture de cellules animales
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
JPH10501686A (ja) 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのdnaのaav仲介送達
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
US7026468B2 (en) 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
ATE286138T1 (de) 1998-03-20 2005-01-15 Univ Pennsylvania Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
FR2778413B1 (fr) 1998-05-07 2000-08-04 Immunotech Sa Nouveaux reactifs et methode de lyse des erythrocytes
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
GB2338236B (en) 1998-06-13 2003-04-09 Aea Technology Plc Microbiological cell processing
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
WO2000024916A1 (en) 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2003501067A (ja) 1999-06-02 2003-01-14 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヘルパーウイルスを要求する組み換えウイルス産生のために有用な組成物及び方法
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
US6334998B1 (en) 1999-12-07 2002-01-01 Parker Hughes Institute Estrogens for treating ALS
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
EP1302542B1 (en) 2000-07-18 2007-06-13 Takeda Pharmaceutical Company Limited Novel physiologically active peptide and use thereof
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
FR2813891B1 (fr) 2000-09-14 2005-01-14 Immunotech Sa Reactif multifonctionnel pour erythrocytes mettant en jeu des carbamates et applications
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
EP1390490B1 (en) 2001-05-24 2009-04-15 Genzyme Corporation Muscle-specific expression vectors
CA2451643C (en) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
CN1617938A (zh) 2002-01-16 2005-05-18 戴诺生物技术有限公司 从单个样品中分离核酸和蛋白质的方法
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
US20050196862A1 (en) * 2002-08-30 2005-09-08 Wooddell Christine I. DNA cassette for cellular expression of small RNA
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
CA2505514A1 (en) 2002-11-06 2004-05-27 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
CA2509494A1 (en) 2002-12-11 2004-06-24 University Of Massachusetts Method of introducing sirna into adipocytes
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
WO2005001103A2 (en) 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2005007676A2 (en) 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
EP1714960B1 (en) 2004-02-09 2018-03-28 Mitsubishi Tanabe Pharma Corporation Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als
WO2005096781A2 (en) 2004-04-06 2005-10-20 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using rna interference
ES2932278T3 (es) 2004-06-01 2023-01-17 Genzyme Corp Composiciones y métodos para prevenir la agregación del vector AAV
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
WO2006066203A2 (en) 2004-12-16 2006-06-22 Alsgen, Llc Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod)
US8614101B2 (en) 2008-05-20 2013-12-24 Rapid Pathogen Screening, Inc. In situ lysis of cells in lateral flow immunoassays
FR2882062B1 (fr) * 2005-02-14 2007-06-15 Commissariat Energie Atomique Vecteurs d'expression stable et de longue duree de sirna et leurs applications
US7625570B1 (en) 2005-03-10 2009-12-01 The Regents Of The University Of California Methods for purifying adeno-associated virus
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
AU2007212700A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts RNA interference agents for therapeutic use
EP2514824A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
CN101528916B (zh) 2006-04-28 2013-09-04 宾夕法尼亚大学托管会 规模可调的aav生产方法
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
US8183219B2 (en) 2007-01-03 2012-05-22 Medtronic, Inc. Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
EP2653873B8 (en) 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
WO2008134646A2 (en) 2007-04-26 2008-11-06 University Of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
HUE029744T2 (en) 2007-07-26 2017-04-28 Uniqure Ip Bv Baculoviral vectors comprising repeated coding sequences with differential codon biases
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2242840B1 (en) 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
JP5328244B2 (ja) 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US10167263B2 (en) 2008-11-20 2019-01-01 Northwestern University Treatment of amyotrophic lateral sclerosis
WO2010136549A2 (en) 2009-05-28 2010-12-02 Deutsches Krebsforschungszentrum Modified aav capsid polypeptides
JP2014501097A (ja) 2009-07-06 2014-01-20 アルナイラム ファーマシューティカルズ, インコーポレイテッド 生物由来物質の産生を高めるための組成物及び方法
EP2568999B1 (en) 2010-05-11 2018-07-11 Mallinckrodt Ard Ip Limited Acth for treatment of amyotrophic lateral sclerosis
EP2422787A1 (en) 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
ES2739804T3 (es) 2011-02-12 2020-02-04 Univ Iowa Res Found Compuestos terapéuticos
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
CA2831969A1 (en) 2011-06-06 2012-12-30 Biocartis S.A. Selective lysis of cells by ionic surfactants
RU2632659C2 (ru) 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
SG10201604810UA (en) * 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
HK1210214A1 (en) * 2012-07-06 2016-04-15 University Of Iowa Research Foundation Modified adeno-associated virus vector compositions
EP2970966A4 (en) * 2013-03-15 2016-10-26 Univ North Carolina SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES
JP2016517278A (ja) * 2013-03-15 2016-06-16 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法
WO2015060722A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
AU2015264263B2 (en) 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
WO2016049230A1 (en) * 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
CN114717264A (zh) * 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) * 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CL2014003146A1 (es) * 2014-11-20 2015-06-12 Univ Santiago Chile Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus.
AU2015370903B2 (en) 2014-12-24 2021-06-17 Uniqure Ip B.V. RNAi induced huntingtin gene suppression
IL297238B2 (en) * 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
IL297576B2 (en) * 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
US20200270635A1 (en) * 2017-05-05 2020-08-27 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3618839A4 (en) * 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
WO2019079242A1 (en) * 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Similar Documents

Publication Publication Date Title
JP2024095717A5 (cg-RX-API-DMAC7.html)
JP2021502060A5 (cg-RX-API-DMAC7.html)
JP2022517174A5 (cg-RX-API-DMAC7.html)
JP2022531861A5 (cg-RX-API-DMAC7.html)
AU2013221212B2 (en) AAV vector compositions and methods for gene transfer to cells, organs and tissues
JP2026027271A5 (cg-RX-API-DMAC7.html)
JP2022500066A5 (cg-RX-API-DMAC7.html)
JP2020537544A5 (cg-RX-API-DMAC7.html)
JP2018516978A5 (cg-RX-API-DMAC7.html)
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
IL292605A (en) CRISPR and AAV strategies for the treatment of x-linked childhood retinoschisis
CA3134485A1 (en) Compositions useful for treatment of pompe disease
JP2023537904A5 (cg-RX-API-DMAC7.html)
JP2022530095A5 (cg-RX-API-DMAC7.html)
JP2022553573A5 (cg-RX-API-DMAC7.html)
JP2020535804A5 (cg-RX-API-DMAC7.html)
FI3953377T3 (fi) Geeniterapioita lysosomaalisiin sairauksiin
JP2022511453A5 (cg-RX-API-DMAC7.html)
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
US20140179003A1 (en) Alternative export pathways for vector expressed rna interference
JP2023528371A5 (cg-RX-API-DMAC7.html)
JP2024530023A5 (cg-RX-API-DMAC7.html)
JP2024534124A5 (cg-RX-API-DMAC7.html)
JP2025513066A5 (cg-RX-API-DMAC7.html)
JP2023509443A5 (cg-RX-API-DMAC7.html)